Compound useful for the treatment of degenerative and inflammatory diseases
A novel compound able to inhibit JAK is disclosed, that comprises a compound according to Formula I: or a pharmaceutically acceptable salt thereof. The compound may be prepared as a pharmaceutical composition, and may be used for the treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6.
1. A compound according to Formula I:
or a pharmaceutically acceptable salt thereof.
2. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound according claim 1 .
3. The pharmaceutical composition according to claim 2 comprising a further therapeutic agent selected from arthritis treatment agents.
4. The pharmaceutical composition according to claim 3 , wherein the further therapeutic agent is an agent selected from analgesics, NSAIDS (non-steroidal anti-inflammatory drugs), and DMARDS (disease-modifying anti-rheumatic drugs).
5. A method for the treatment of rheumatoid arthritis, comprising administering an amount of a compound of claim 1 , sufficient to effect said treatment.
6. The method according to claim 5 , wherein the compound according to claim 1 is administered in combination with one or more further therapeutic agents selected from arthritis treatment agents.
7. The method according to claim 5 , wherein the compound according to claim 1 is administered in combination with one further therapeutic agent selected from arthritis treatment agents.
8. A method for the treatment of rheumatoid arthritis, comprising administering an amount of a pharmaceutical composition of claim 2 , sufficient to effect said treatment.
9. A method for the treatment of rheumatoid arthritis, comprising administering an amount of a pharmaceutical composition of claim 2 , sufficient to effect said treatment.
10. The method according to claim 3 , wherein said pharmaceutical composition is administered in combination with a further therapeutic agent selected from arthritis treatment agents.
11. The method according to claim 9 , wherein said pharmaceutical composition is administered in combination with a further therapeutic agent selected from arthritis treatment agents.
12. The method according to claim 6 , wherein the further therapeutic agent is an agent selected from analgesics, NSAIDS (non-steroidal anti-inflammatory drugs), and DMARDS (disease-modifying anti-rheumatic drugs).
13. The method according to claim 7 , wherein the further therapeutic agent is an agent selected from analgesics, NSAIDS (non-steroidal anti-inflammatory drugs), and DMARDS (disease-modifying anti-rheumatic drugs).
14. The method according to claim 10 , wherein the further therapeutic agent is an agent selected from analgesics, NSAIDS (non-steroidal anti-inflammatory drugs), and DMARDS (disease-modifying anti-rheumatic drugs).
15. The method according to claim 11 , wherein the further therapeutic agent is an agent selected from analgesics, NSAIDS (non-steroidal anti-inflammatory drugs), and DMARDS (disease-modifying anti-rheumatic drugs).